A 37-year-old man on dulaglutide for type 2 diabetes developed acute pancreatitis after his dose was increased from 0.75 mg to 1.5 mg weekly, highlighting the importance of monitoring pancreatic enzyme levels with GLP-1 agonist therapy.
Lipase 1,508The patient's lipase was dramatically elevated (normal is <60) following a dose increase of dulaglutide from 0.75 mg to 1.5 mg weekly, confirming acute pancreatitis
What the researchers found
A 37-year-old male with type 2 diabetes who had been taking dulaglutide 0.75 mg weekly for approximately two years developed acute pancreatitis two weeks after his dose was increased to 1.5 mg weekly. Lipase was markedly elevated at 1,508 (normal is typically <60), and CT abdomen showed peripancreatic fat stranding consistent with acute pancreatitis. Symptoms included epigastric pain radiating to the back, nausea, and vomiting — developing after his last dose of Trulicity at the higher dosage.
Why it matters
With millions of patients now taking GLP-1 agonists for diabetes and obesity, even rare side effects affect large numbers of people. While pancreatitis is listed as a potential risk with all GLP-1 agonists, documented cases remain scarce in the literature. This case is especially notable because the pancreatitis appeared to be triggered by a dose increase — relevant as many patients are titrated up for better glycemic control or weight loss.
How the study worked
This is a single-patient case report describing clinical presentation, laboratory findings (elevated lipase at 1,508), imaging (CT scan showing peripancreatic fat stranding), medication history, and temporal association between dulaglutide dose increase and symptom onset.
What this study cannot tell us
As a single case report, this cannot establish causation — only temporal association between dulaglutide dose increase and pancreatitis. Other potential causes (gallstones, alcohol, hypertriglyceridemia) were not fully detailed in the abstract. Case reports represent the lowest level of clinical evidence and cannot determine incidence rates or population-level risk.
How to read the evidence
This is a single case report — the lowest level of clinical evidence. While it provides a well-documented example of a potential adverse drug reaction, it cannot prove causation or estimate risk frequency.
When this study was published
Published in 2023, this case report is relevant to the current landscape of rapidly expanding GLP-1 agonist prescribing for both diabetes and obesity.
The bigger picture
As GLP-1 agonists become some of the most prescribed drugs worldwide — driven by both diabetes management and the obesity epidemic — cataloging their adverse effects becomes increasingly important. Pancreatitis has been a debated safety concern since the early days of GLP-1 agonists. Case reports like this contribute to pharmacovigilance and help refine clinical guidelines for monitoring and dose titration.
Questions still open
- Is the risk of pancreatitis specifically elevated during dose increases of GLP-1 agonists, or does it occur at any dose level?
- Should pancreatic enzyme monitoring be routine during GLP-1 agonist therapy, especially at higher doses used for obesity treatment?
- Do different GLP-1 agonists (dulaglutide vs. semaglutide vs. liraglutide) carry different pancreatitis risk profiles?
Common questions
How common is pancreatitis with GLP-1 agonists like Trulicity?
What symptoms should patients on Trulicity watch for?
Read the original research
Dulaglutide (Trulicity)-Induced Acute Pancreatitis: A Case Report.
Cureus, 15(5), e38630
Citation
Khan, Abu Baker; Shah, Aimal; Ahmad, Saad; Khan, Moiz I; Amir, Ahsan. (2023). Dulaglutide (Trulicity)-Induced Acute Pancreatitis: A Case Report.. Cureus, 15(5), e38630. https://doi.org/10.7759/cureus.38630